TY - JOUR
T1 - Vasopressin analgesia
T2 - Specificity of action and non-opioid effects
AU - Kordower, Jeffrey H.
AU - Bodnar, Richard J.
N1 - Funding Information:
This research was supported in part by NIH GRSG 5-S05-RR07064 and PSC/CUNY Grant 6-63210 to RJB. We thank Dr. M. Manning for his generous gift of the dPTyr(me)AVP. Endo Laboratories for the naloxone hydrochloride, and Pennick inc. for the morphine sulfate. We also thank Drs. M. Manning. W. H. Sawyer. and G. Nilaver for helpful comments and criticisms.
PY - 1984
Y1 - 1984
N2 - Recent neuroanatomical and behavioral evidence has indicated that vasopressin (VP) increases pain thresholds. In the present study intracerebroventricular (ICV) administration of both arginine VP (AVP: 75-500 ng) and 1-deamino-8-D-arginine vasopressin (DDAVP: 150-500 ng) elevated tail flick latencies. Oxytocin (OXY, ICV), also elevated tail-flick latencies (150-1000 ng); however this increase was accompanied by "barrel-roll" seizure activity. VP analgesia was eliminated by pretreatment with 1-deamino-penicillamine-2(O-methyl)tyrosine-AVP (dPTyr(me)AVP: 500 ng, ICV), a VP antagonist, but not naloxone (1 or 10 μg, ICV), suggesting that VP modulates nonciceptive thresholds through its own binding sites. Conversely, pretreatment with naloxone (1 μg, ICV) but not dPTyr(me)AVP (1μg, ICV) attenuated the analgesic efficacy of systemic morphine (10 mg/kg), further dissociating VP and central opiate analgesic processes. Finally, systemic pretreatment with dexamethasone potentiated VP analgesia. These data support the notion that VP is a specific non-opioid pain inhibitor.
AB - Recent neuroanatomical and behavioral evidence has indicated that vasopressin (VP) increases pain thresholds. In the present study intracerebroventricular (ICV) administration of both arginine VP (AVP: 75-500 ng) and 1-deamino-8-D-arginine vasopressin (DDAVP: 150-500 ng) elevated tail flick latencies. Oxytocin (OXY, ICV), also elevated tail-flick latencies (150-1000 ng); however this increase was accompanied by "barrel-roll" seizure activity. VP analgesia was eliminated by pretreatment with 1-deamino-penicillamine-2(O-methyl)tyrosine-AVP (dPTyr(me)AVP: 500 ng, ICV), a VP antagonist, but not naloxone (1 or 10 μg, ICV), suggesting that VP modulates nonciceptive thresholds through its own binding sites. Conversely, pretreatment with naloxone (1 μg, ICV) but not dPTyr(me)AVP (1μg, ICV) attenuated the analgesic efficacy of systemic morphine (10 mg/kg), further dissociating VP and central opiate analgesic processes. Finally, systemic pretreatment with dexamethasone potentiated VP analgesia. These data support the notion that VP is a specific non-opioid pain inhibitor.
KW - 1-deamino-8-D-arginine vasopressin
KW - Arginine vasopressin
KW - Oxytocin
KW - Pain
KW - dPTyr(me)AVP
UR - http://www.scopus.com/inward/record.url?scp=0021211891&partnerID=8YFLogxK
U2 - 10.1016/0196-9781(84)90017-2
DO - 10.1016/0196-9781(84)90017-2
M3 - Article
C2 - 6494025
AN - SCOPUS:0021211891
SN - 0196-9781
VL - 5
SP - 747
EP - 756
JO - Peptides
JF - Peptides
IS - 4
ER -